trending Market Intelligence /marketintelligence/en/news-insights/trending/3OCsqd0aUBVtxL7HsHXxyw2 content esgSubNav
In This List

AbbVie, J&J's Imbruvica gets FDA approval for chronic graft versus host disease

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


AbbVie, J&J's Imbruvica gets FDA approval for chronic graft versus host disease

The U.S. Food and Drug Administration approved AbbVie Inc.'s Imbruvica to treat adult patients with chronic graft-versus-host-disease who failed one or more treatments.

With this approval, Imbruvica is the first and only therapy specifically approved for adults with chronic graft-versus-host-disease, a serious and debilitating potential consequence of stem cell or bone marrow transplant.

The approval was based on the results of a phase 1b/2 trial where 67% of patients who received the treatment saw improvements in their symptoms. Also, 48% of the patients experienced sustained response for at least 20 weeks.

Imbruvica is jointly developed and commercialized by AbbVie's Pharmacyclics LLC and Janssen Biotech Inc., a Johnson & Johnson company. The companies are continuing the drug's clinical development, including phase 3 studies evaluating it in multiple disease areas.